PTC Therapeutics Raises 2026 Product Revenue Guidance Amid Sephience Expansion
PTC Therapeutics (PTCT) reported record product revenue for the third quarter, leading management to raise its full-year 2026 product revenue guidance to a range of $960 million to $990 million. The company's growth is being driven by the continued expansion of Sephience and strong operational execution across its portfolio. Looking ahead, the company is focusing on key regulatory milestones, specifically targeting a Q4 2026 filing for ST-920. CEO Matthew Klein expressed confidence in the company's trajectory, citing solid performance as the primary driver for the updated financial outlook.
Tickers: $PTCT
Topics: earnings report management guidance revenue growth
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)